Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia

Cardiovascular Research

Volumn 59, Issue 2, 2003, Pages 271-276

  Riksen, Niels P ^a   Rongen, Gerard A ^a   Blom, Henk J ^a   Russel, Frans G M ^a   Boers, Godfried H J ^a   Smits, Paul ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adenosine; Atherosclerosis; Hyperhomocysteinemia; Pathophysiology; S Adenosylhomocysteine hydrolase

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; S ADENOSYLMETHIONINE;

ATHEROGENESIS; ATHEROMATOSIS; BRAIN BLOOD FLOW; CELL DAMAGE; CORONARY RISK; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEART PROTECTION; HYPEREMIA; HYPERHOMOCYSTEINEMIA; HYPOXIA; METABOLIC BALANCE; MICRODIALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; PROTEIN METABOLISM; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR;

ADENOSINE; CARDIOVASCULAR DISEASES; HOMEOSTASIS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; RECEPTORS, PURINERGIC P1; S-ADENOSYLHOMOCYSTEINE;

EID: 0142090595     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(03)00462-0     Document Type: Review

References (60)

1. Mudd S.H., Skovby F., Levy H.L., et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet. 37:1985;1-31.
2. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J. Am. Med. Assoc. 288:2002;2015-2022.
3. Mudd S.H., Levy H.L., Kraus J.P. Disorders of transsulfuration. Scriver C.R., Beaudet A.L., Sly W.S., Vale D. The metabolic and molecular basis of inherited disease. 2001;2007-2056 McGraw-Hill, New York.
4. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 56:1969;111-128.
5. Medina M., Urdiales J.L., Amores-Sanchez M.I. Roles of homocysteine in cell metabolism: old and new functions. Eur J Biochem. 268:2001;3871-3882.
6. Nappo F., De Rosa N., Marfella R., et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. J. Am. Med. Assoc. 281:1999;2113-2118.
7. Chambers J.C., McGregor A., Jean-Marie J., Obeid O.A., Kooner J.S. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 99:1999;1156-1160.
8. Stamler J.S., Osborne J.A., Jaraki O., et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 91:1993;308-318.
9. Mansoor M.A., Guttormsen A.B., Fiskerstrand T., et al. Redox status and protein binding of plasma aminothiols during the transient hyperhomocysteinemia that follows homocysteine administration. Clin Chem. 39:1993;980-985.
10. Blom H.J., van der Molen E.F. Pathobiochemical implications of hyperhomocysteinemia. Fibrinolysis. 8:1994;86-87.
11. Wang H., Yoshizumi M., Lai K., et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem. 272:1997;25380-25385.
12. Dayal S., Bottiglieri T., Arning E., et al. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine β-synthase-deficient mice. Circ Res. 88:2001;1203-1209.
13. Yi P., Melnyk S., Pogribna M., et al. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem. 275:2000;29318-29323.
14. Hultberg B., Andersson A., Isaksson A. Hypomethylation as a cause of homocysteine-induced cell damage in human cell lines. Toxicology. 147:2000;69-75.
15. Ueland P.M. Pharmacological and biochemical aspects of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase. Pharmacol Rev. 34:1982;223-253.
16. Kredich N.M., Martin D.V. Jr. Role of S-adenosylhomocysteine in adenosine-mediated toxicity in cultured mouse T lymphoma cells. Cell. 12:1977;931-938.
17. Kerins D.M., Koury M.J., Capdevila A., Rana S., Wagner C. Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr. 74:2001;723-729.
18. Hershfield M.S., Mitchell B.S. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. Scriver C.R., Beaudet A.L., Sly W.S., Vale D. The metabolic and molecular basis of inherited disease. 2001;2585-2625 McGraw-Hill, New York.
19. Lloyd H.G., Schrader J. Adenosine metabolism in the guinea pig heart: the role of cytosolic S-adenosyl-L-homocysteine hydrolase, 5′ -nucleotidase and adenosine kinase. Eur Heart J. 14:(Suppl I):1993;27-33.
20. Lloyd H.G., Deussen A., Wuppermann H., Schrader J. The transmethylation pathway as a source for adenosine in the isolated guinea-pig heart. Biochem J. 252:1988;489-494.
21. Achterberg P.W., de Tombe P.P., Harmsen E., de Jong J.W. Myocardial S-adenosylhomocysteine hydrolase is important for adenosine production during normoxia. Biochim Biophys Acta. 840:1985;393-400.
22. Kroll K., Deussen A., Sweet I.R. Comprehensive model of transport and metabolism of adenosine and S-adenosylhomocysteine in the guinea pig heart. Circ Res. 71:1992;590-604.
23. Deussen A., Lloyd H.G., Schrader J. Contribution of S-adenosylhomocysteine to cardiac adenosine formation. J Mol Cell Cardiol. 21:1989;773-782.
24. Deussen A., Stappert M., Schafer S., Kelm M. Quantification of extracellular and intracellular adenosine production: understanding the transmembranous concentration gradient. Circulation. 99:1999;2041-2047.
25. Tabrizchi R., Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol Ther. 91:2001;133-147.
26. Sciotti V.M., Van Wylen D.G. Attenuation of ischemia-induced extracellular adenosine accumulation by homocysteine. J Cereb Blood Flow Metab. 13:1993;208-213.
27. Schrader J., Schutz W., Bardenheuer H. Role of S-adenosylhomocysteine hydrolase in adenosine metabolism in mammalian heart. Biochem J. 196:1981;65-70.
28. Deussen A., Borst M., Schrader J. Formation of S-adenosylhomocysteine in the heart. I: An index of free intracellular adenosine. Circ Res. 63:1988;240-249.
29. Sadick N., German D.C., McHale P.A., Greenfield J.C. Jr., Kredich N.M. Functional and reactive hyperemia are unaltered by homocysteine in conscious dogs. Basic Res Cardiol. 80:1985;280-290.
30. Kingsbury M.P., Robinson H., Flores N.A., Sheridan D.J. Investigation of mechanisms that mediate reactive hyperaemia in guinea-pig hearts: role of K(ATP) channels, adenosine, nitric oxide and prostaglandins. Br J Pharmacol. 132:2001;1209-1216.
31. Chen Y.F., Li P.L., Zou A.P. Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation. 106:2002;1275-1281.
32. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.N., Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 53:2001;527-552.
33. Jackson E.K. Adenosine: a physiological brake on renin release. Annu Rev Pharmacol Toxicol. 31:1991;1-35.
34. Smits P., Lenders J.W., Willemsen J.J., Thien T. Adenosine attenuates the response to sympathetic stimuli in humans. Hypertension. 18:1991;216-223.
35. Rongen G.A., Lenders J.W., Lambrou J., et al. Presynaptic inhibition of norepinephrine release from sympathetic nerve endings by endogenous adenosine. Hypertension. 27:1996;933-938.
36. Belardinelli L., Linden J., Berne R.M. The cardiac effects of adenosine. Prog Cardiovasc Dis. 32:1989;73-97.
37. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 74:1986;1124-1136.
38. Mullane K. Myocardial preconditioning. Part of the adenosine revival. Circulation. 85:1992;845-847.
39. Miura T., Ogawa T., Iwamoto T., Shimamoto K., Iimura O. Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning. Circulation. 86:1992;979-985.
40. Edlund A., Siden A., Sollevi A. Evidence for an anti-aggregatory effect of adenosine at physiological concentrations and for its role in the action of dipyridamole. Thromb Res. 45:1987;183-190.
41. Cristalli G., Vittori S., Thompson R.D., et al. Inhibition of platelet aggregation by adenosine receptor agonists. Naunyn Schmiedebergs Arch Pharmacol. 349:1994;644-650.
42. Deguchi H., Takeya H., Urano H., et al. Adenosine regulates tissue factor expression on endothelial cells. Thromb Res. 91:1998;57-64.
43. Minamino T., Kitakaze M., Asanuma H., et al. Endogenous adenosine inhibits P-selectin-dependent formation of coronary thromboemboli during hypoperfusion in dogs. J Clin Invest. 101:1998;1643-1653.
44. Cronstein B.N. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol. 76:1994;5-13.
45. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 414:2001;916-920.
46. Cronstein B.N., Levin R.I., Belanoff J., Weissmann G., Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest. 78:1986;760-770.
47. Sajjadi F.G., Takabayashi K., Foster A.C., Domingo R.C., Firestein G.S. Inhibition of TNF-α expression by adenosine: role of A3 adenosine receptors. J Immunol. 156:1996;3435-3442.
48. Flamand N., Boudreault S., Picard S., et al. Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene biosynthesis in human neutrophils. Am J Respir Crit Care Med. 161:2000;S88-S94.
49. Maggirwar S.B., Dhanraj D.N., Somani S.M., Ramkumar V. Adenosine acts as an endogenous activator of the cellular antioxidant defense system. Biochem Biophys Res Commun. 201:1994;508-515.
50. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol. 22:2002;364-373.
51. Dubey R.K., Gillespie D.G., Mi Z., Suzuki F., Jackson E.K. Smooth muscle cell-derived adenosine inhibits cell growth. Hypertension. 27:1996;766-773.
52. Dubey R.K., Gillespie D.G., Shue H., Jackson E.K. A(2B) receptors mediate antimitogenesis in vascular smooth muscle cells. Hypertension. 35:2000;267-272.
53. Dubey R.K., Gillespie D.G., Jackson E.K. Adenosine inhibits collagen and total protein synthesis in vascular smooth muscle cells. Hypertension. 33:1999;190-194.
54. Takiguchi Y., Nagano M., Ikeda Y., Nakashima M. Early administration of YT-146, an adenosine A2 receptor agonist, inhibits neointimal thickening after rat femoral artery endothelium injury. Eur J Pharmacol. 281:1995;205-207.
55. Dubey R.K., Gillespie D.G., Jackson E.K. A(2B) adenosine receptors stimulate growth of porcine and rat arterial endothelial cells. Hypertension. 39:2002;530-535.
56. Peyot M.L., Gadeau A.P., Dandre F., et al. Extracellular adenosine induces apoptosis of human arterial smooth muscle cells via A(2b)-purinoceptor. Circ Res. 86:2000;76-85.
57. Van Belle H. Nucleoside transport inhibition: a therapeutic approach to cardioprotection via adenosine? Cardiovasc Res. 27:1993;68-76.
58. Thornton J.D., Liu G.S., Olsson R.A., Downey J.M. Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction. Circulation. 85:1992;659-665.
59. Dubey R., Mi Z., Gillespie D.G., Jackson E.K. Dysregulation of extracellular adenosine levels by vascular smooth muscle cells from spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol. 21:2001;249-254.
60. Watanabe M., Osada J., Aratani Y., et al. Mice deficient in cystathionine β-synthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci USA. 92:1995;1585-1589.